Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1711967 | 0.91 | AR (0.59) | ARPGR | |
| SCHEMBL1712222 | 0.91 | AR (0.59) | ARPGR | |
| SCHEMBL1712149 | 0.91 | AR (0.59) | ARPGR | |
| SCHEMBL1712228 | 0.91 | AR (0.70) | ARPGR | |
| SCHEMBL1712495 | 0.86 | AR (0.59) | ARPGR | |
| SCHEMBL1712233 | 0.86 | AR (0.59) | ARPGR | |
| SCHEMBL1969730 | 0.86 | AR (0.56) | ARPGR | |
| SCHEMBL1711966 | 0.86 | AR (0.58) | ARPGR | |
| SCHEMBL1711970 | 0.83 | AR (0.54) | ARPGR | |
| SCHEMBL1712212 | 0.76 | AR (0.62) | ARPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2344460-B1 | NOVEL IMIDAZOLIDINE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | AKASHI THERAPEUTICS INC (US) | 2015-08-12 | — | — | EP | disclosed |
| US-8383608-B2 | Imidazolidine compounds as androgen receptor modulators | DART THERAPEUTICS LLC | 2013-02-26 | — | — | US | disclosed |
| US-20120178718-A1 | NOVEL IMIDAZOLIDINE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | AKASHI THERAPEUTICS, INC. | 2012-07-12 | — | — | US | disclosed |
| EP-2344460-A1 | NOVEL IMIDAZOLIDINE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | Galapagos N.V. (BE) | 2011-07-20 | — | — | EP | disclosed |
| US-7968581-B2 | Imidazolidine compounds as androgen receptor modulators | GALAPAGOS NV (BE) | 2011-06-28 | — | — | US | disclosed |
| US-20100113547-A1 | NOVEL IMIDAZOLIDINE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | AKASHI THERAPEUTICS, INC. | 2010-05-06 | — | — | US | disclosed |
| WO-2010029119-A1 | NOVEL IMIDAZOLIDINE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | GALAPAGOS NV (BE) | 2010-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178718-A1 | NOVEL IMIDAZOLIDINE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | AR, FSHR, GNRHR | AR 1/4885PGR 226/4885 |
| US-20100113547-A1 | NOVEL IMIDAZOLIDINE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | AR, FSHR, GNRHR | AR 1/4885PGR 173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.